Pfizer CEO Bourla Bets the Viagra Playbook Can Crack the Obesity Market — Barrons.com

What happened

Pfizer CEO Albert Bourla says the company can use the commercial approach behind Viagra to compete in obesity drugs. Pfizer acquired berobenatide through its $10 billion purchase of Metsera in late 2025 and plans a weekly version in 2028, followed by a monthly injection.

Confirmed

Global impact / market context

Pfizer is entering a market already led by Eli Lilly and Novo Nordisk, so its ability to sell and distribute a successful treatment will matter alongside the drug itself. If the plan works, obesity medicines could add revenue and strengthen Pfizer’s business beyond its existing areas.

Analyst inference

The article describes obesity medicines as a large, resilient market and points to Lilly’s stock performance as evidence of investor interest. Pfizer’s product is still a candidate, with a planned 2028 launch, leaving a substantial wait before it can contribute sales.

Confirmed

What to watch

1. Whether Pfizer’s weekly berobenatide formulation is ready for the planned 2028 debut; delays or a different launch schedule would postpone any potential obesity-drug sales. Analyst inference
2. Whether Pfizer follows the weekly version with the planned monthly injection, which could give patients another dosing option and affect how the company competes. Proposed
3. How Pfizer puts its Viagra-era direct-sales experience into practice for obesity medicines, including whether patients are willing to pay out of pocket as they once did. Analyst inference

Evidence

• Original source link unavailable